The aim of the registry is to include all psoriasis patients in the country who receive systemic therapy. In our most urgent target group – patients receiving biological therapy with treatment costs of approximately SEK 130,000 per patient and year – over half of country’s patients are registered.
Systemic treatment entails potential risks for the patients and it is unfortunate that we have not previously been able to monitor how recommendations for the treatment have been applied. Procedures for initiation of treatment, drug dosage, sampling, etc. can vary considerably throughout the country. A national evaluation of forms of treatment is urgent with regard to the benefit of therapy for both patients and for society at large from a health economics standpoint.
A national registry is essential in order to gain, as quickly as possible, important experience-based information regarding drug limitations, such as serious side effects.
Our primary target group is psoriasis patients who are candidates for systemic treatment and this group is primarily treated by dermatologists, i.e. in specialist care. Secondly, there is a vision to expand the patient base and then also include psoriasis patients receiving conventional light therapy (UVB) in order to evaluate the benefits, long-term effects and side effects of this treatment and make comparisons with systemic treatment.
Note: Variable lists are updated on a regular basis and should therefore be seen as preliminary. For the latest version, please contact the registry.
Category: Other areas
Certification level: 2
Tack för att du hjälper oss!